The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Legend Biotech's Revenue for the
three
months ended in Mar. 2026 was $305 Mil. Legend Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was $7 Mil.
Hence, Legend Biotech's Receivables Turnover for the
three
months ended in Mar. 2026 was 41.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Legend Biotech Receivables Turnover Related Terms
Legend Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Legend Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LEGN vs TVTX, ORKA, CRSP: Receivables Turnover Comparison
For the Biotechnology subindustry, Legend Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Legend Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a Receivables Turnover of 41.23 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #16 out of 841 companies in the Biotechnology industry, placing it in the top 1.9%.
Is Legend Biotech's Receivables Turnover too high?
Legend Biotech's current Receivables Turnover is 41.23. The Biotechnology industry median Receivables Turnover is 5.29. Legend Biotech's value of 41.23 is 679.4% above this industry median. Based on the distribution chart, Legend Biotech ranks #16 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Receivables Turnover compare to TVTX and ORKA?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #16 out of 841 companies for Receivables Turnover. This places Legend Biotech in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Legend Biotech's value of 41.23 is 679.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current Receivables Turnover of 41.23 is 679.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Legend Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current Receivables Turnover is 41.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.95, compared to a current price of $25.46 — trading 74.5% below its estimated fair value. The current Receivables Turnover is 41.23 and 679.4% above the Biotechnology industry median of 5.29. Legend Biotech's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Receivables Turnover is 41.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $25.46 is trading 74.5% below its estimated GF Value™ of $99.95.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
Receivables Turnover: 41.23
GF Value™: $99.95 vs. price of $25.46 (74.5% below fair value)
Industry Position: 679.4% above the Biotechnology median (#16 of 841)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score
Get the complete analysis for LEGN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
